After opening the day in green share markets in India have continued the momentum and are presently trading comfortably above the dotted line. Sectoral indices are trading on a mixed note, with stocks in the realty sector and stocks in the auto sector witnessing maximum buying interest. While stocks in the IT sector are leading the losses.

The BSE Sensex is trading up by 245 points (up 0.7%) and the NSE Nifty is trading up by 75 points (up 0.7%). Meanwhile, the BSE Mid Cap index is trading up by 0.8%, while the BSE Small Cap index is trading up by 0.9%. The rupee is trading at 64.68 to the US$.

In news from stocks in the pharma sector. Sun Pharma share price is among the top losers on the bourses today after the United States Food & Drug Administration (USFDA) made three observations after inspecting its Halol, Gujarat plant.

India’s largest drugmaker said that the USFDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceuticals Industries Ltd’s Halol facility. At the conclusion of the inspection, the agency issued a Form 483 with three observations.

As per USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.

Sun Pharma’s US supplies were hit over the past year after the US FDA found violations of manufacturing practices at the company’s Halol manufacturing unit. US FDA conducted its first inspection of the facility in 2014 and another in December 2015. The company was given a warning letter with six observations, preventing it from making fresh filings of new drug applications.

In November-December 2016, Sun Pharma’s Halol plant was re- inspected and the US FDA issued Form 483 with nine observations.

At the time of writing, Sun Pharma share price was trading down by 2%.